Startups
GlioCure
Angers, France
GlioCure is an Angers-based French biotechnology company developing investigational medicines for diseases of glial cells, particularly glioblastoma and other difficult-to-treat brain tumours. Founded in September2016 by neuroscience researchers Joël Eyer and Claire Lépinoux-Chambaud with entrepreneur Louis-Marie Bachelot, it originated in research at the University of Angers, Inserm and McGill University. The legal company is GlioCure SA, Angers RCS/SIREN822444840; its April2021 conversion to a société anonyme supersedes old SAS website footer text. Its May2026 announcement confirms continuing development of GC01.1, an injectable formulation of NFL-TBS.40-63 peptide, in final non-regulatory preclinical development for glioblastoma and brain metastases from triple-negative breast cancer. A European formulation patent numbered4593865 was granted with GlioCure as sole owner. These are investigational research and intellectual-property milestones; no clinical efficacy or regulatory approval is asserted. Its wider research portfolio includes GC02 for paediatric brain tumours and GlioVector drug-delivery technology. The public management directory names CEO Louis-Marie Bachelot, Research Director Claire Lépinoux-Chambaud and Pharmaceutical Development Director Paul Baldwin. Four published scientific and medical advisers are external experts. Historical appointments and dated named research staff are qualified separately. Actual financing includes prior equity/quasi-equity, a2020 EUR250K Bpifrance French Tech Seed convertible subscription, an April2021 EUR274500 capital-increase tranche and2021 EUR336K repayable public advances. Cumulative EUR600K seed and nearlyEUR500K bridge totals are not added as extra cash. Patient-association investments through the dedicated GlioCure Capital holding are distinguished from direct donations and from crowdfunding-platform services. Company targets, an unfunded EU Seal of Excellence, and in-kind research awards are not treated as completed cash rounds.
Team
Carl SimonssonCure’nCaps Business Unit Manager (historical2021 appointment) |
 Claire Lépinoux-ChambaudDirector (historical April2021 board constitution) · Research Director · Co-Founder (September2016) |
Clément SanchezResearch Engineer (dated issuer2023–2025 staff captions; current tenure unverified) |
 Emeline TabouretScientific and Medical Advisory Board Member (external) |
 Jean-Pierre BizzariScientific and Medical Advisory Board Member (external) |
 Joël EyerCo-Founder (September2016); Scientific and Medical Adviser (historical2017–2020) |
 Joël RichardScientific and Medical Advisory Board Member (external) |
 Louis-Marie BachelotDirector (historical April2021 board constitution) · Chairman and Chief Executive Officer · Co-Founder (September2016) |
 Marc-Eric HalatschScientific and Medical Advisory Board Member (external) |
Olivier MeyerVice-President Corporate Development (historical2021 announcement; current tenure unverified) |
 Paul BaldwinDirector of Pharmaceutical Development |
Sandrine CourtèsDirector of Preclinical Development and Intellectual Property (appointed2021; current tenure unverified) |